XEN1101 for Major Depressive Disorder

• ClinicalTrials.gov Identifier: NCT04827901
• Recruitment Status: Recruiting
• First Posted: April 1, 2021
• Last Update Posted: November 10, 2022
• Sponsor: James Murrough
• Collaborators: Baylor College of Medicine; National Institute of Mental Health (NIMH)
• Information provided by (Responsible Party): James Murrough, Icahn School of Medicine at Mount Sinai

Study Description

Brief Summary:

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

Condition or disease	Intervention/treatment	Phase
Major Depressive Disorder	Drug: XEN1101; Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This is a phase II, randomized, parallel-arm, placebo-controlled clinical trial were 60 patients with major depressive disorder will be randomized in 1:1 fashion to XEN1101 (N=30) or matching placebo (N=30).
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Proof of Concept Randomized Controlled Trial of XEN1101 for the Treatment of Major Depressive Disorder
• Actual Study Start Date: October 19, 2021
• Estimated Primary Completion Date: January 2024
• Estimated Study Completion Date: February 2024

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: XEN1101; Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.	Drug: XEN1101; two 10 mg capsules
Placebo Comparator: Placebo; Subjects will take a matching placebo daily for eight weeks.	Drug: Placebo; matching placebo

Outcome Measures

Primary Outcome Measures :

1. Change in activation within the reward circuit by fMRI [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
   The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by fMRI during an Incentive Flanker Task.

Secondary Outcome Measures :

1. Change in Montgomery-Åsberg Depression Rating Scale Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
   The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
2. Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
   The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. The 16 items cover the nine symptom domains of major depression and are rated on a scale of 0-3. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
3. Change in Snaith-Hamilton Pleasure Scale (SHAPS) [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
   The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
4. Change in Temporal Experience of Pleasure Scale [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
   The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items. Total scores range is 16-108. Lower scores indicate greater levels of anhedonia.
5. Change in Clinical Global Impression Scale [ Time Frame: Baseline (week 0), End of treatment (week 8) ]

   This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment.

   Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients".

   The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

1. Written informed consent (and assent when applicable) obtained from subject
2. Ability for subject to comply with the requirements of the study as determined by the PI;
3. Men and women, age 18-65 years;
4. Participants must meet DSM-5 criteria for current depressive disorder (major depressive disorder [MDD]) in a major depressive episode (MDE) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV);
5. Clinically significant anhedonia as determined by a SHAPS score ≥ 20 at screening;
6. Current illness severity is at least moderate, defined as a score of ≥4 on the CGI-S Scale;
7. If female of childbearing potential, must agree to use of a medically accepted form of contraception, or else agree to abstinence until 6 months after the last dose of study drug.

Exclusion Criteria

1. A primary psychiatric diagnosis other than MDD as defined by DSM-5;
2. Has a history of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features, or bipolar I or II disorder.
3. History of non-response to >4 adequate antidepressant trials in the current episode as determined by the Antidepressant Treatment Response Questionnaire (ATRQ);
4. History of non-response to electroconvulsive therapy in the current depressive episode;
5. A current diagnosis of depression with peripartum onset;
6. Diagnosis of a major neurocognitive disorder;
7. Meets criteria for a substance use disorder within the past 6 months, with the exception of nicotine use disorder;
8. Patient shows signs of retinal macular disease, or retinal pigment epithelium abnormality prior to randomization.
9. Male patients, if heterosexually active with partner who is female of childbearing potential, pregnant, or breastfeeding, who are unwilling to agree to barrier contraception for the treatment period and for at least 6 months after the last dose of study drug. Female partners of male participants who are unwilling to use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug.
10. Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study or the 6 months following;
11. Inability to swallow capsules;
12. Any contraindication to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
13. Positive urine toxicology screen for drugs of abuse at the time of screening*;
14. Use of any dis-allowed medication according to the study protocol**;
15. Serious and imminent risk of self-harm or violence as determined by the PI;
16. Extreme illness severity as defined by a CGI-S score >=6;
17. Any current active suicidal ideation as measured by a Columbia Suicide Severity Rating Scale [C-SSRS] score of greater than 2 during the past month at the time of screening
18. History of suicide attempt in past 2 years;
19. Any unstable medical condition, including as follows; 19.1. History of skin or retinal pigment epithelium abnormalities caused by ezogabine; 19.2. Family history of sudden death of unknown cause; 19.3. Clinically significant abnormalities of laboratory tests, physical examination, or ECG; 19.4. History or presence of long QT syndrome; 19.5. QT corrected by Fridericia's formula (QTcF) > 450 msec; 19.6. Alanine transferase (ALT; SGPT) or aspartate transferase (AST; SGOT) levels >3 times the upper limit of normal (ULN) at screening;
20. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Contacts and Locations

Contacts

Contact: Sara Hameed, B.A.; 212-585-4622; sara.hameed@mssm.edu

Contact: Amelia Karim; 212-585-4621; amelia.karim@mssm.edu

Locations

United States, New York

Icahn School of Medicine at Mount Sinai; Recruiting

New York, New York, United States, 10029

Contact: Sara Hameed, B.A. 212-585-4622 sara.hameed@mssm.edu

Contact: Amelia Karim 212-585-4621 amelia.karim@mssm.edu

Principal Investigator: James W Murrough, MD, PhD

United States, Texas

Baylor College of Medicine; Recruiting

Houston, Texas, United States, 77030

Contact: Tabish Iqbal 713-798-4095 tiqbal@bcm.edu

Principal Investigator: Sanjay Mathew, MD

Sponsors and Collaborators

James Murrough

Baylor College of Medicine

National Institute of Mental Health (NIMH)

Investigators

• Principal Investigator: James W Murrough, MD, PhD; Icahn School of Medicine at Mount Sinai

More Information

• Responsible Party: James Murrough, Associate Professor, Psychiatry, Icahn School of Medicine at Mount Sinai
• ClinicalTrials.gov Identifier: NCT04827901
• Other Study ID Numbers: GCO 16-0374-02; 4R33MH111932-03 ( U.S. NIH Grant/Contract )
• First Posted: April 1, 2021
• Last Update Posted: November 10, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: All of the individual participant data collected during the trial, after deidentification.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)
• Time Frame: Immediately following publication. No end date.
• Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Any purpose. Other NDCT Database
• URL: https://nda.nih.gov

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by James Murrough, Icahn School of Medicine at Mount Sinai:

depression; anhedonia; major depressive disorder; investigational medication; potassium channel; KCNQ

Additional relevant MeSH terms:

Disease; Depressive Disorder; Depression; Depressive Disorder, Major; Pathologic Processes; Mood Disorders; Mental Disorders; Behavioral Symptoms